Literature DB >> 22297235

The SSRIs: advantages, disadvantages and differences.

R Lane1, D Baldwin, S Preskorn.   

Abstract

The highly specific mechanism of action of the selective serotonin re-uptake inhibitors (SSRIs) confers advantages on this group, relative to other classes of antidepressant, and thus represents a significant advance in the pharmacotherapy of depression. Whilst their clinical efficacy is equivalent to that of the tricyclic antidepressants (TCAs), the SSRIs have a greatly reduced risk of toxicity in overdose and have been shown to be significantly better tolerated. Specifically, the SSRIs have a low incidence of anticholinergic effects and are essentially devoid of cardiotoxicity. This tolerability advantage may be of significance in improving compliance and hence cost-effectiveness of treatment, particularly in the long term. Despite a lack of sedative effect, there is evidence that SSRIs are more effective than TCAs in the treatment of depression with anxiety. In addition, the SSRIs have been shown to be effective in obsessive-compulsive disorder, panic disorder and social phobia. Although superior efficacy has not been demonstrated for any one of the SSRIs, the structural diversity of this group is reflected in emerging qualitative and quantitative differences in side effects and drug interaction potential. Many of these differential features reflect important variations in pharmacological and pharmacokinetic profiles, including dosage flexibility, washout times, dose-plasma level proportionality and age-related changes in plasma levels. Fluoxetine, for example, has a considerably longer half-life than other SSRIs and side effects and drug interactions may thus occur for an extended period following discontinuation of treatment. Significant differences in the potential for drug interactions in this group are related to their relative potency for inhibition of important liver drug-metabolising enzymes including CYPIID6, CYPIA2 and CYPIIIA4. Large comparative clinical trials of the different SSRIs have yet to be undertaken; however, the differences that have already become apparent provide important information enabling the physician to choose an SSRI appropriate to the individual patient.

Entities:  

Year:  1995        PMID: 22297235     DOI: 10.1177/0269881195009002011

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  13 in total

1.  The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study.

Authors:  U F Malt; O H Robak; H P Madsbu; O Bakke; M Loeb
Journal:  BMJ       Date:  1999-05-01

2.  Discriminative stimulus properties of tianeptine.

Authors:  Tevfik Alici; Hakan Kayir; M Oguz Aygoren; Esra Saglam; I Tayfun Uzbay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

Review 3.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 4.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 5.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

6.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

7.  Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?

Authors:  C Sánchez; E Meier
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

Review 8.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

9.  Postpartum psychiatric disorders : guidelines for management.

Authors:  A Buist
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

10.  Long-term effects of fluoxetine or vehicle administration during pregnancy on behavioral outcomes in guinea pig offspring.

Authors:  Raphael Vartazarmian; Saima Malik; Glen B Baker; Patricia Boksa
Journal:  Psychopharmacology (Berl)       Date:  2004-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.